Both investigators contributed equally and should be considered as senior authors.
Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice
Article first published online: 1 AUG 2008
Copyright © 2008 John Wiley & Sons, Ltd.
The Journal of Gene Medicine
Volume 10, Issue 10, pages 1071–1082, October 2008
How to Cite
Kucerova, L., Matuskova, M., Pastorakova, A., Tyciakova, S., Jakubikova, J., Bohovic, R., Altanerova, V. and Altaner, C. (2008), Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J. Gene Med., 10: 1071–1082. doi: 10.1002/jgm.1239
- Issue published online: 5 SEP 2008
- Article first published online: 1 AUG 2008
- Manuscript Revised: 19 JUN 2008
- Manuscript Accepted: 19 JUN 2008
- Manuscript Received: 22 FEB 2008
- FIDURA Capital Consult GmbH
- SPP Foundation
- human mesenchymal stem cells;
- cellular therapy;
- retrovirus vector;
- bystander effect
Previously, we validated capability of human adipose tissue-derived mesenchymal stem cells (AT-MSC) to serve as cellular vehicles for gene-directed enzyme prodrug molecular chemotherapy. Yeast fusion cytosine deaminase : uracil phosphoribosyltransferase expressing AT-MSC (CDy-AT-MSC) combined with systemic 5-fluorocytosine (5FC) significantly inhibited growth of human colon cancer xenografts. We aimed to determine the cytotoxic efficiency to other tumour cells both in vitro and in vivo.
CDy-AT-MSC/5FC-mediated proliferation inhibition against a panel of human tumour cells lines was evaluated in direct and indirect cocultures in vitro. Antitumour effect was tested on immunodeficient mouse model in vivo.
Although culture expansion of CDy-AT-MSC sensitized these cells to 5FC mediated suicide effect, expanded CDy-AT-MSC/5FC still exhibited strong bystander cytotoxic effect towards human melanoma, glioblastoma, colon, breast and bladder carcinoma in vitro. Most efficient inhibition (91%) was observed in melanoma A375 cell line when directly cocultured with 2% of therapeutic cells CDy-AT-MSC/5FC. The therapeutic paradigm of the CDy-AT-MSC/5FC system was further evaluated on melanoma A375 xenografts on nude mice in vivo. Complete regression in 89% of tumours was achieved when 20% CDy-AT-MSC/5FC were co-injected along with tumour cells. More importantly, systemic CDy-AT-MSC administration resulted in therapeutic cell homing into subcutaneous melanoma and mediated tumour growth inhibition.
CDy-AT-MSC capability of targeting subcutaneous melanoma offers a possibility to selectively produce cytotoxic agent in situ. Our data further demonstrate beneficial biological properties of AT-MSC as a cellular vehicle for enzyme/prodrug therapy approach to molecular chemotherapy. Copyright © 2008 John Wiley & Sons, Ltd.